BNP/CALL/MODERNA/80/0.1/20.12.24 | Delayed Deutsche Boerse AG 04:50:32 2024-07-09 am EDT | ||
| 3.98 EUR | +2.05% |
|
| Current month | -5.80% | ||
| 1 month | -44.21% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-09 | 3.98 | +2.05% |
| 24-07-08 | 3.9 | -4.18% |
| 24-07-05 | 4.07 | -0.97% |
| 24-07-04 | 4.11 | +5.66% |
| 24-07-03 | 3.89 | -2.51% |
Delayed Quote Deutsche Boerse AG
Last update July 09, 2024 at 04:50 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
BNP Paribas
|
| WKN | PZ1AWT |
| ISIN | DE000PZ1AWT3 |
| Date issued | 2023-11-13 |
| Strike | 80 $ |
| Maturity | 2024-12-20 (165 Days) |
| Parity | 10 : 1 |
| Emission price | 1.53 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 8.57 € |
|---|---|
| Lowest since issue | 1.32 € |
| Spread | 0.01 € |
| Spread % | 0.25% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
116.4
USD
Average target price
145.9
USD
Spread / Average Target
+25.25%
- Stock Market
- Warrants
- Warrant
